Eagle Biosciences Announces Agreement with Genetic Analysis AS for Distribution in North America
“North America is for sure going to accelerate the growth in the human microbiome market moving forward. We at GA are very excited to fuel this growth with our GA-map®…
Genetic Analysis awarded NOK 16 million to develop microbiome marker to aid treatment of Inflammatory Bowel Disease
In this project, GA will develop an easy to use, in vitro diagnostic test that profiles gutmicrobiota to predict disease progression and treatment regimes in patients with ulcerativecolitis. The development…
Genetic Analysis Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Norwegian molecular diagnostic company Genetic Analysis AS to its coalition of companies leading the research and development of FDA-approved…
Genetic Analysis AS announces that a patent was granted in the US, from family WO2016120494A
“METHOD AND PRODUCT FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP’S”. In March 2019, GA signed a license agreement with the university NMBU’ Tech transfer office that secured GA global…
Genetic Analysis AS announces that a patent was granted in India, from family WO2012080754A2
“OLIGONUCLEOTIDE PROBE SET AND METHODS OF MICROBIOTA PROFILING”. We are very pleased to inform that our patent “Oligonucleotide probe set and methods of microbiota profiling” has been granted in India…
Genetic Analysis AS announces that two patents were granted in Russia and EU, from family WO2016156251A1
“METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS”. New IP secured – Important patents enhancing the use of GA-map® granted in EU and Russia. The object of this family of patents relates…
Successful share issue and change in the management team
Successful share issue Genetic Analysis AS announces the successful private placement of NOK 34.3 million. The issue was oversubscribed and completed in two tranches; the first tranche closed on June 19th was aimed at…